P8A:SGX
Cordlife Group Ltd
SGD 0.12
0.00%
(0.00) 1D
Okt 12, 9:49:20 AM GMT+8 · SGD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa P8A...
Mkt. cap
32.37M
Avg. na dami
1.22K
Dami
0.00
Mataas nang 52-wk
SGD 0.26
Mababa nang 52-wk
SGD 0.10
EPS
-SGD 0.04
Mga natitirang share
267.53M
Bilang ng mga empleyado
111
Mkt. cap
32.37M
Avg. na dami
1.22K
Dami
0.00
Mataas nang 52-wk
SGD 0.26
Mababa nang 52-wk
SGD 0.10
EPS
-SGD 0.04
Mga natitirang share
267.53M
Bilang ng mga empleyado
111
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
MarketWatch
·
14 oras ang nakalipas
These surprising stocks could be some of the biggest drivers of S&P 500 earnings growth
Bloomberg.com
·
6 oras ang nakalipas
US Stock Futures Rise Ahead of Busy Earnings Week: Markets Wrap
MarketWatch
·
3 araw ang nakalipas
There’s a ‘monstrous bull market’ developing under the surface of the S&P 500. This hedge-fund manager tells you where it’s at.
Investor's Business Daily
·
2 araw ang nakalipas
Dow Jones Futures: Tesla Flies On Roadster As Investors Question Anthropic Valuation
Profile
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Tungkol sa Cordlife Group Ltd
CEOYiu Pang Fai
Mga Empleyado111
ItinatagMay 2, 2001
Headquarters-
SektorHealth care provider
Websitecordlife.com